ERBB2 and breast carcinoma: The mAb trastuzumab, targeting the HER2 in patients with HER2 overexpressed/amplified (HER2+) breast cancer (approximately 20% of breast cancer diagnoses worldwide; ref. 2) provides a clear example (3).